Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × mCRC × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 472 Carcinoma, Non-Small-Cell Lung 442 Prostatic Neoplasms 298 Multiple Myeloma 238 Neoplasms 229 Colorectal Neoplasms 219 Leukemia, Myeloid, Acute 192 Squamous Cell Carcinoma of Head and Neck 186 Lung Neoplasms 184 Neoplasm Metastasis 177 Carcinoma, Hepatocellular 169 Pancreatic Neoplasms 160 Melanoma 154 Triple Negative Breast Neoplasms 144 Recurrence 131 Ovarian Neoplasms 131 Glioblastoma 120 Lymphoma 119 Brain Neoplasms 118 Leukemia, Lymphocytic, Chronic, B-Cell 109 Precursor Cell Lymphoblastic Leukemia-Lymphoma 106 Carcinoma, Renal Cell 106 Sarcoma 105 Stomach Neoplasms 103 Lymphoma, Large B-Cell, Diffuse 103 Head and Neck Neoplasms 103 Myelodysplastic Syndromes 93 Rectal Neoplasms 90 Endometrial Neoplasms 87 Urinary Bladder Neoplasms 84

Interventions

trifluridine tipiracil drug combination 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Jinan Central Hospital

Phase 2 Not yet recruiting

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡